公开(公告)号：EP4460321A2

公开(公告)日：2024-11-13

申请号：EP23737737.9

申请日：2023-01-05

申请人： Cedars-Sinai Medical Center

发明人： KIM, Hyung L. ,  WANG, Yanping ,  SU, Shengchen

IPC分类号： A61K38/17 ,  A61K31/454 ,  C07K14/17 ,  C07D401/04 ,  A61K38/53

公开(公告)号：EP4430381A1

公开(公告)日：2024-09-18

申请号：EP22893895.7

申请日：2022-11-11

申请人： Black Light Surgical, Inc. ,  Cedars-Sinai Medical Center

发明人： BORTNIK, Bartosz ,  BUTTE, Pramod ,  O'BRIEN, Mike ,  YU GU, Ruo ,  LOWELL, Augustus P. ,  HARRIS, Todd L. ,  FORD, Russell B. ,  SOLOMON, Edward G. ,  LEVATICH, Mark ,  SHARMA, Dominic V. ,  MOORE, Steven

IPC分类号： G01N21/64 ,  A61B5/00 ,  G01J3/02 ,  G01J3/10 ,  G01N21/17

CPC分类号： G01N21/6456 ,  G01N21/6408 ,  G01N21/6486 ,  G01J3/4406 ,  G01J3/0264 ,  G01J3/027 ,  G01J3/0248 ,  G01J3/28

公开(公告)号：EP4265716A3

公开(公告)日：2024-01-24

申请号：EP23184643.7

申请日：2017-06-16

申请人： Cedars-Sinai Medical Center

发明人： SAREEN, Dhruv ,  ORNELAS, Loren A ,  SVENDSEN, Clive

IPC分类号： C12N5/074 ,  C12N15/09 ,  C12N5/10

摘要： Described herein are methods and compositions related to generation of induced pluripotent stem cells (iPSCs). Improved techniques for establishing highly efficient, reproducible reprogramming using non-integrating episomal plasmid vectors. Using the described reprogramming protocol, one is able to consistently reprogram non-T cells with close to 100% success from non-T cell or non-B cell sources. Further advantages include use of a defined reprogramming media E7 and using defined clinically compatible substrate recombinant human L-521. Generation of iPSCs from these blood cell sources allows for recapitulation of the entire genomic repertoire, preservation of genomic fidelity and enhanced genomic stability.

公开(公告)号：EP4296285A2

公开(公告)日：2023-12-27

申请号：EP23192639.5

申请日：2019-04-26

申请人： Cedars-Sinai Medical Center ,  Prometheus Biosciences, Inc. ,  Dr. Falk Pharma GmbH

发明人： BILSBOROUGH, Janine ,  MCGOVERN, Dermot P. ,  TARGAN, Stephan ,  POTDAR, Alka ,  WATKINS, Jeffry, D. ,  DICKERSON, Cindy, T.

IPC分类号： C07K16/28

摘要： Described herein are methods and systems for identifying subjects suitable for treatment with an inhibitor of CD30L activity or expression, such as an anti-CD30L antibody. Methods and systems disclosed herein identify subjects suitable for treatment based on a presence of a genotype that is indicative of a disease or condition in the subject for which an inhibitor of CD30L is a suitable treatment. Exemplary conditions include both Crohn's disease and primary sclerosing cholangitis. Compositions used to detect the genotypes described herein, and methods of using them are also provided.

公开(公告)号：EP4263585A1

公开(公告)日：2023-10-25

申请号：EP21911988.0

申请日：2021-12-20

申请人： Cedars-Sinai Medical Center

发明人： MCGOVERN, Dermot, P. ,  BILSBOROUGH, Janine ,  TARGAN, Stephan, R. ,  POTDAR, Alka

IPC分类号： C07K14/525 ,  C12Q1/6883 ,  A61P1/00

公开(公告)号：EP4256086A1

公开(公告)日：2023-10-11

申请号：EP21901329.9

申请日：2021-11-30

申请人： Cedars-Sinai Medical Center

发明人： GONSKY, Rebecca ,  POTDAR, Alka

IPC分类号： C12Q1/6883 ,  G16B15/20 ,  G16B40/20

公开(公告)号：EP4218775A1

公开(公告)日：2023-08-02

申请号：EP23177120.5

申请日：2018-08-02

申请人： Cedars-Sinai Medical Center

发明人： MARBAN, Eduardo ,  GRIGORIAN, Lilian

IPC分类号： A61K35/12 ,  A61K35/34 ,  A61K35/545 ,  A61K48/00 ,  C12N5/095 ,  G01N33/574 ,  A61P35/00

摘要： Described herein are methods and compositions related to treating cancer using cardiosphere derived cells (CDCs) and/or extracellular vesicles (EVs). In some embodiments, the EVs are heart-derived EVs (e.g., cardiosphere-derived exosomes, CDC-derived exosomes, cardiosphere-derived microvesicles, CDC-derived microvesicles, or combinations thereof). In some embodiments, methods of treating cancer in a subject are provided. In some embodiments, CDCs and/or EVs are administered to a subject to treat cancer. In some embodiments, the CDCs and/or EVs are provided in a pharmaceutical formulation.

公开(公告)号：EP4196212A1

公开(公告)日：2023-06-21

申请号：EP21856823.6

申请日：2021-08-13

申请人： Cedars-Sinai Medical Center

发明人： REZAIE, Ali ,  PIMENTEL, Mark ,  MELMED, Gil Y.

IPC分类号： A61N5/06 ,  A61M39/16 ,  A61B1/06 ,  A61B18/18 ,  A61B18/24 ,  A61L2/10

公开(公告)号：EP4194001A1

公开(公告)日：2023-06-14

申请号：EP22201939.0

申请日：2016-04-22

申请人： Cedars-Sinai Medical Center

发明人： ABROL, Ravinder ,  PANDOL, Stephen ,  PHAM, Hung

IPC分类号： A61K38/06 ,  A61K38/08 ,  A61K38/26 ,  A61P3/00 ,  A61P3/10 ,  A61P7/00 ,  A61P7/12 ,  A61K38/07 ,  A61K31/19 ,  A61K31/366 ,  A61K31/37 ,  A61K38/28 ,  A61K47/61 ,  A61P3/04

摘要： Described herein are methods and compositions for treatment of diabetes and/or obesity. Bitter oligopeptide molecules formulated for enteric delivery modulate signals involving receptors facing the lumen of the gastrointestinal tract, said signaling related hormones such as glucagon-like peptide-1 (GLP-1) and peptide tyrosine-tyrosine (PYY) that involve inhibition of gastric emptying and appetite. As a novel way to treat diabetes with limited adverse effects the described invention uses body's own endocrine system to treat diabetes, which is an advantage over current therapies that may simply provide disease management without cure or require more radical approaches such as surgical intervention.

公开(公告)号：EP4188360A2

公开(公告)日：2023-06-07

申请号：EP21852216.7

申请日：2021-08-02

申请人： Cedars-Sinai Medical Center ,  Fortem Neurosciences, Inc.

发明人： KORONYO, Maya ,  BLACK, Keith L. ,  KAVANAUGH, Jack

IPC分类号： A61K31/202 ,  A61K31/232 ,  A61K31/27 ,  A61P25/28